BXP price target raised to $77 from $71 at Truist

Truist raised the firm’s price target on BXP (BXP) to $77 from $71 and keeps a Hold rating on the shares. At the company’s triannual investor day in New York this week, the management highlighted outperformance of trophy properties vs. broader office assets, path towards higher occupancy, development- driven growth and access to multiple capital sources that include private equity, the analyst tells investors in a research note. Life science was no longer a prominent discussion topic, but instead, the management sees residential opportunities via development & dispositions, the firm added.